Weight Loss Benefits NASH, No Matter How It's Done

Share this content:
Weight Loss Benefits NASH, No Matter How It's Done
Weight Loss Benefits NASH, No Matter How It's Done

MONDAY, Aug. 24, 2015 (HealthDay News) -- Weight loss can improve nonalcoholic steatohepatitis (NASH) in obese or overweight people, whether excess pounds are shed through lifestyle changes or weight-loss surgery, according to research published in the August issue of Gastroenterology.

In one study, researchers found that overweight and obese people who achieved a weight loss of 10 percent or more after one year of lifestyle changes involving a low-calorie diet and exercise experienced reductions in nonalcoholic fatty liver disease activity score. In addition, 90 percent experience resolution of NASH, and 45 percent showed regression of fibrosis. Weight loss of 7 to 10 percent also reduced disease severity in some patients, including men and those without diabetes.

In the other study, researchers found that NASH disappeared in 85 percent of obese patients one year after they had weight-loss surgery. The success rate was higher among those with mild NASH (94 percent) than among those with severe disease (70 percent).

"In summary, we have now evidence that weight loss may promote NASH regression, possibly altering the natural history of disease," Giulio Marchesini, M.D., of the University of Bologna, Italy, and colleagues write in an editorial accompanying the studies. "We need to make people more aware of the risks of obesity-associated NASH, and validated weight-reducing strategies should be offered to all patients; behavior therapy, drugs, and surgery should be integrated with each other and with societal interventions, aimed at decreasing the obesiogenic environment. The final recipe is weight loss for healthy liver!"

Abstract 1
Full Text
Abstract 2
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »